Showing results (281-290 of 330) with videos related to

Sort By:
Pageof 33
Cancer Investigation|May 7, 2013
Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot studyP Queirolo, A Morabito, S Laurent, et al.
The Review of Scientific Instruments|August 1, 2016
Absolute dosimetric characterization of Gafchromic EBT3 and HDv2 films using commercial flat-bed scanners and evaluation of the scanner response function variabilityS N Chen, M Gauthier, M Bazalova-Carter, et al.
Il Giornale Di Chirurgia|November 1, 1996
[An update on parathyroid surgery]P Campi, R Cristofani, M F Burattini, et al.
Tumori|April 4, 1998
Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrualG De Palo, T Camerini, E Marubini, et al.
Diabetes & Metabolism|June 30, 2004
Flexible treatment of gestational diabetes modulated on ultrasound evaluation of intrauterine growth: a controlled randomized clinical trialM Bonomo, I Cetin, M P Pisoni, et al.
The Cancer Journal From Scientific American|April 13, 1999
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapyG Gasparini, M Toi, R Miceli, et al.
Oncology|October 17, 2002
Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancerS Palmeri, V Leonardi, M Tamburo De Bella, et al.
International Journal of Oncology|April 30, 2011
Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancerS Pignata, R Lauria, F Perrone, et al.
Oncology|November 29, 2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trialS Pignata, G Scambia, A Savarese, et al.
Cancer Research|June 11, 1999
Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell linesP Giacomini, E Giorda, R Fraioli, et al.
Pageof 33